Drew Burch: Yes, sure. Thanks, Matt. This has obviously been a bit of a correction year, and we are, I think from a correction standpoint, the TAM and SAM markets that estimates that people use, including us, will probably be adjusted down for a bit of a step down. And as you say, and it’s about what the growth rates are coming back out. And as you identified, we have our base business and we have the COVID program material. I would say the, the example we had where we took single-digit millions out of the COVID is a good example of how we see activity already starting to shift across a broader base, non-COVID programs. And again, our material inputs are fungible in that way. We do definitely have 2023’s looked COVID CleanCap to work around.
But we also have a lot of confidence in the long-term growth rates and, in particular, look forward to, as we announced two partnerships that are in the CRISPR gene editing area today. We look forward to what we’ve seen will be a very exciting growth and market uptake for CRISPR gene editing, which is both the therapy in itself in a tool to make cell and gene therapies. And I think a lot of the activity there has been well publicized. So we’re looking forward to a much broader and less concentrated customer base with many more programs progressing and are very optimistic about the growth in the mRNA, gene cell therapy and CRISPR gene editing markets over that 5-year period.
Operator: Our next question comes from the line of Michael Ryskin with Bank of America. Your line is open.
Michael Ryskin: Great. Thanks, I’m actually going to ask a two part. First, I want to follow up on exactly the last point, but maybe I’ll just drill in on the near term, a little bit more on the non-COVID piece. I mean you’ve had just on dollar terms, declines there for three or four quarters in a row now and you’re guiding to another decline in 4Q, I believe, can that segment grow next year or have you sort of zeroed out all the adjustments and all the rebasing that needs to happen? Just because there was a period of such an elevated growth in the prior years and especially as you say, some of that stuff can move between COVID and non-COVID pretty easily. I’m just trying to figure out what the right floor for that is when that can start growing again.
And this year, in the 150s, is that a 4? Or is there still some more excess non-COVID come out of that? And then if I can squeeze in a second part. I want to ask about the cost cuts, the $30 million. First, I want to make sure is any of that having a benefit in 4Q? Or is it only really kicking in next year, and if you could just provide a little bit more specifics, is it on the, it sounds like it was pretty heavily on the manufacturing side, but also on SG&A. If you could just sort of break that through across the different buckets, how we should think about it? That would be helpful. Thanks.
Kevin Herde: Yes. Mike, I’ll start with the second part of your question on the cost realignment initiative. Yes, I would say geographically on the P&L, it’s roughly going to be 50% hitting the COGS line. The operational reductions primarily in our Nucleic Acid Production segment sort of right size those operations to the post-pandemic volumes that we’re seeing and the other 50% predominantly going to hit our SG&A line. The focus a little bit more on the G&A component of that we continue to see the appropriate investments in our commercial channel paying dividends for us over time. So basically 50-50 split between COGS and SG&A. We have been cognizant certainly of the revenue declines throughout the course of this year and investors’ cut back certain discretionary spend items.
